US2006188905A1PendingUtilityA1

Process

44
Assignee: DYNAL BIOTECH ASAPriority: Jan 17, 2005Filed: Jan 17, 2006Published: Aug 24, 2006
Est. expiryJan 17, 2025(expired)· nominal 20-yr term from priority
Y10T428/2998G01N 33/5434Y10T436/143333C12Q 1/68
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A process for the preparation of coated polymer particles containing superparamagnetic crystals, said process comprising reacting surface-functionalized, superparamagnetic crystal-containing polymer particles of diameter less than 0.5 μm with at least one polyisocyanate and at least one diol.

Claims

exact text as granted — not AI-modified
1 . A process for the preparation of coated polymer particles containing superparamagnetic crystals, said process comprising reacting surface-functionalized, superparamagnetic crystal-containing polymer particles of diameter less than 0.5 μm with at least one polyisocyanate and at least one diol.  
     
     
         2 . A process as claimed in  claim 1  wherein at least two diols are employed.  
     
     
         3 . A process as claimed in  claim 1  wherein said diol is selected from the group consisting of polyethylene glycols and diols of formula HO((CH 2 ) m O) n H (where n is an integer of 1 to 15 and m is an integer of 2 to 6).  
     
     
         4 . A process as claimed in  claim 2  wherein said diols are diethyleneglycol and tetraethyleneglycol.  
     
     
         5 . A process as claimed in  claim 2  wherein one of said diols is polyethyleneglycol.  
     
     
         6 . A process as claimed in  claim 1  wherein said polyisocyanate is 4,4-methylene bis(phenylisocyanate) or a polyisocyanate comprising 4,4-methylene bis(phenylisocyanate) with CH 2 -phenylisocyanate residues (Desmodur™).  
     
     
         7 . A process as claimed in  claim 1  wherein said polyisocyanate is a diisocyanate.  
     
     
         8 . A process as claimed in  claim 1  wherein said particles are, in a first stage, reacted with a mixture of polyisocyanate and at least one diol in which the polyisocyanate is in a molar excess relative to the diol(s) and, in a second stage, subsequently reacted with at least one diol.  
     
     
         9 . A process as claimed in  claim 8  wherein two diols are used in the first stage of the reaction and one or two diols used in the second stage.  
     
     
         10 . A process as claimed in  claim 9  wherein diethyleneglycol and tetraethyleneglycol are used in both stages of the reaction.  
     
     
         11 . A process as claimed in  claim 1  wherein the particles are, in a first stage, reacted with polyisocyanate in the absence of diol, and, in a second stage, reacted with at least one diol.  
     
     
         12 . A process as claimed in  claim 11  wherein one dial is employed and said diol is a polyethylene glycol.  
     
     
         13 . A process as claimed in  claim 1  wherein the particles are amine functionalised.  
     
     
         14 . A process as claimed in  claim 1  wherein said surface-functionalized polymer particles are nitrated and reduced styrene-divinylbenzene polymer particles.  
     
     
         15 . A process as claimed in  claim 1  wherein the diameter of the polymer particles is between 150 and 250 nm.  
     
     
         16 . A process as claimed in  claim 1  in which said coated particle is subsequently tosylated.  
     
     
         17 . A process as claimed in  claim 1  wherein subsequent to the coating reaction, said particles are coupled to a drug molecule, reporter moiety or ligand.  
     
     
         18 . A process as claimed in  claim 17  wherein said ligand is a monoclonal antibody, polyclonal antibody, antibody fragment, nucleic acid, oligonucleotide, protein, oligopeptide, polysaccharide, sugar, peptide, peptide encoding nucleic acid molecule, antigen or drug.  
     
     
         19 . A process as claimed in  claim 18  wherein said ligand is streptavidin.  
     
     
         20 . A particle obtainable by the process of  claim 1 .  
     
     
         21 . A method of using the particle as claimed in  claim 20  in an assay.  
     
     
         22 . A method as claimed in  claim 21  wherein said assay is for the detection of nucleic acid or is an immunoassay.  
     
     
         23 . A method of using the particle as claimed in  claim 21  in hydrophobic interaction chromatography or reversed phase chromatography.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.